Clinical Trials Browser

Brain Diseases, Brain Neoplasms, Breast Diseases, Breast Neoplasms, Central Nervous System Diseases, Neoplasms, Neoplasms by Site, Central Nervous System Neoplasms

NCT04791384 2026-03-31

Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Phase 1/2 Terminated

5 enrolled

Breast

Breast Neoplasms

NCT05573126 2026-03-20

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Phase 1/2 Recruiting

95 enrolled

Breast

Breast Neoplasms

NCT07222215 2026-01-22

CAPELA

Phase 2 Recruiting

297 enrolled

Breast

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT06691035 2025-12-04

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Phase 1 Recruiting

18 enrolled

Breast

Breast Neoplasms

NCT06201234 2025-12-01

ELEMENT

Phase 2 Recruiting

176 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07159451 2025-12-01

POP-ELA

Phase 2 Recruiting

140 enrolled

Breast

Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Phase 2 Recruiting

174 enrolled

Breast

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

Phase 3 Completed

478 enrolled 16 charts 1 FDA

Breast

Breast Neoplasms

NCT05618613 2025-05-09

ELONA

Phase 1/2 Terminated

4 enrolled

Breast

Breast Neoplasms

NCT06938711 2025-04-22

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast

Breast Neoplasms

NCT04797728 2022-10-26

ELIPSE

Phase EARLY_PHASE1 Completed

23 enrolled

Breast

Breast Neoplasms

NCT02650817 2022-08-18

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Phase 1 Completed

16 enrolled

Breast

Breast Neoplasms